Skip to main content
. 2021 Sep 27;11:19154. doi: 10.1038/s41598-021-98113-6

Table 2.

Patients (%) reporting adverse events (AEs).

Type of AEs No. (% of total n = 14)
Any AEs 1 (7)
Serious AE (grade ≥ 3) 3 (21)
AEs leading to discontinuation 1 (7)
AEs leading to dose reduction 0 (0)
Death due to combination therapy 0 (0)
Death due to disease progression 9 (64)